Last reviewed · How we verify
Tenofovir 1% vaginal gel
At a glance
| Generic name | Tenofovir 1% vaginal gel |
|---|---|
| Also known as | TFV, 9-[2-(Phosphonomethoxy)propyl]adenine |
| Sponsor | CONRAD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding (PHASE4)
- Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women (PHASE1)
- Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women (PHASE2)
- Safety and Acceptability of a Vaginal Microbicide (PHASE2)
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women (PHASE2)
- Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery (PHASE1)
- Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women (PHASE2)
- Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir 1% vaginal gel CI brief — competitive landscape report
- Tenofovir 1% vaginal gel updates RSS · CI watch RSS
- CONRAD portfolio CI